Ultralife Corporation Reports Third Quarter Results


NEWARK, N.Y., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the third quarter ended September 30, 2025 with the following results:

  • Sales of $43.4 million increased 21.5% from $35.7 million for the third quarter of 2024; excluding Electrochem, sales of $36.6 million increased 2.5%
  • Gross profit of $9.6 million, or 22.2% of revenue, compared to $8.7 million, or 24.3% of revenue, for the third quarter of 2024
  • Operating loss of $1.0 million, reflecting one-time non-recurring costs of $1.1 million, including a $.5 million provision to close our Calgary facility, compared to operating income of $0.5 million for the third quarter of 2024
  • GAAP EPS of ($0.07) compared to $0.02 for the third quarter of 2024
  • Adjusted EBITDA of $2.0 million compared to $1.9 million for the third quarter of 2024
  • Backlog of $90.1 million exiting the third quarter of 2025 compared to $84.5 million exiting the second quarter of 2025

During the third quarter of 2025, Ultralife made the decision to close its battery pack assembly facility located in Calgary, Canada. Accordingly the Company recorded a $.5 million charge to cover employee severance and termination costs, the remaining lease costs which run through July 31, 2026 and the estimated costs to close the facility and relocate the equipment and inventory to the Company’s facility in Houston, Texas. Management expects to complete the closure in the first quarter of 2026 and to realize estimated annual savings of approximately $.8 million thereafter primarily resulting from the reduction of labor and the elimination of the leased facility.

“Although revenue grew 2.5% organically and 21.5% including the Electrochem acquisition for the third quarter, supply chain issues caused manufacturing inefficiencies in our Battery & Energy Products business and orders continued to be delayed in our Communications Systems business, both of which impacted overall profitability. In response, we are intensifying our lean and process improvement initiatives, improving supply chain resiliency and rationalizing our manufacturing operations,” said Mike Manna, President and Chief Executive Officer.

“These actions are critical to ensuring we are best prepared to optimize the operating leverage of our business model as we advance several new products into qualification and production, and capitalize on an expanding pipeline of opportunities consisting primarily of large, multi-year programs,” added Manna. “Our priorities remain converting long-term new product development efforts into revenue, advancing vertical integration in the oil & gas segment, and maintaining a strong focus on operational efficiency initiatives to deliver sustainable profitable growth and maximizing the value of our global brand.”

Third Quarter 2025 Financial Results

Revenue was $43.4 million, an increase of $7.7 million, or 21.5%, as compared to revenue of $35.7 million for the third quarter of 2024. Battery & Energy Products sales increased 22.8% to $39.9 million compared to $32.5 million last year reflecting the inclusion of Electrochem Solutions, Inc. (“Electrochem”). Excluding Electrochem, Battery & Energy Products sales increased 1.9% with government/defense sales increasing 19.0%, reflecting strong demand from a U.S.-based global prime, partially offset by a 5.7% decrease in commercial sales, primarily reflecting declines in oil & gas and medical sales. Communications Systems sales increased 8.2% to $3.4 million compared to $3.2 million for the same period last year.

Gross profit was $9.6 million, or 22.2% of revenue, compared to $8.7 million, or 24.3% of revenue, for the same quarter a year ago. Battery & Energy Products gross margin was 22.1%, compared to 24.7% last year, primarily due to manufacturing inefficiencies resulting from quality issues associated with some incoming raw materials lowering factory throughput at some of our locations and less favorable sales mix. Communications Systems gross margin was 23.3% compared to 20.0% last year, primarily due to product mix.

Operating expenses were $10.6 million, compared to $8.2 million for the third quarter of 2024, reflecting the inclusion of Electrochem and one-time non-recurring costs of $1.1 million related to the closing of our Calgary facility, costs related to our acquisition of Electrochem and transition to Ultralife systems, and litigation expenses incurred for our cyber insurance claim. Operating expenses were 24.4% of revenue compared to 22.9% of revenue for the year-earlier period. Excluding the one-time costs, operating expenses were 21.9% of revenues for the third quarter of 2025.

Operating loss was $1.0 million compared to operating income of $.5 million last year, primarily resulting from the one-time non-recurring expenses incurred and lower gross margin for our Battery & Energy Products segment in 2025.  

Other expense, reported below operating income was $.8 million, comprised of interest expense from the financing of our Electrochem acquisition on October 31, 2024 and foreign currency gains from the strengthening of the U.S. dollar, compared to $.2 million for the same period last year.   

Net (loss) income attributable to Ultralife Corporation was ($1.2) million or ($0.07) per basic and diluted share on a GAAP basis, compared to $.3 million or $0.02 per diluted share for the third quarter of 2024.

Adjusted EBITDA, defined as EBITDA including non-cash, stock-based compensation expense, was $2.0 million for the third quarter of 2025, or 4.7% of sales, compared to $1.9 million, or 5.4% of sales, for the year-earlier period. On a trailing twelve-month basis, adjusted EBITDA was $15.5 million or 8.3% of sales.

See the “Non-GAAP Financial Measures” section of this release for a reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.

About Ultralife Corporation

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government/defense and commercial customers across the globe.

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.

Conference Call Information

Ultralife will hold its third quarter earnings conference call today at 8:30 ET.

To ensure a fast and reliable connection to our investor conference call, we now require participants dialing in by phone to register using the following link prior to the call: https://register-conf.media-server.com/register/BI0301fd92021249ef830e0c9c7be9f917. This will eliminate the need to speak with an operator. Once registered, dial-in information will be provided along with a personal identification number. Should you register early and misplace your details, you can simply click back on this same link at any time to register and view this information again. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at http://investor.ultralifecorporation.com. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include uncertain global economic conditions including the impact of tariffs and inflation, reductions in revenues from key customers, delays or reductions in U.S. and foreign military spending, acceptance of our new products on a global basis, and disruptions, delays or material price increases in our supply of raw materials and components due to business conditions, new or additional tariffs, global conflicts, weather or other factors not under our control. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife’s financial results is included in Ultralife’s Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.







ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Dollars in Thousands)
(Unaudited)

ASSETS






September 30,
2025

December 31,
2024

Current Assets:



Cash$9,260
$6,854
Trade Accounts Receivable, Net30,929
29,370
Inventories, Net52,747
51,363
Prepaid Expenses and Other Current Assets7,683
9,573
Total Current Assets100,619
97,160





Property, Plant and Equipment, Net40,536
40,485
Goodwill45,336
45,006
Other Intangible Assets, Net23,407
24,557
Deferred Income Taxes, Net8,212
8,413
Other Non-Current Assets4,136
4,830

Total Assets
$222,246
$220,451


LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
Accounts Payable$14,164
$14,160
Current Portion of Long-Term Debt3,781
2,750
Accrued Compensation and Related Benefits2,935
2,911
Accrued Expenses and Other Current Liabilities12,818
9,470
Total Current Liabilities33,698
29,291
Long-Term Debt, Net46,518
51,502
Deferred Income Taxes1,358
1,443
Other Non-Current Liabilities3,239
4,028
Total Liabilities84,813
86,264





Shareholders' Equity:



Common Stock2,109
2,107
Capital in Excess of Par Value192,622
191,828
Accumulated Deficit(32,918)
(34,442)
Accumulated Other Comprehensive Loss(3,058)
(4,006)
Treasury Stock(21,492)
(21,492)
Total Ultralife Equity137,263
133,995
Non-Controlling Interest170
192
Total Shareholders’ Equity137,433
134,187





Total Liabilities and Shareholders' Equity$222,246
$220,451



ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(In Thousands Except Per Share Amounts)
(Unaudited)









Three-Month Period Ended
Nine-Month Period Ended

September 30,
September 30,
September 30,
September 30,

2025
2024
2025
2024
Revenues:






Battery & Energy Products$39,946
$32,529

$132,134
$104,201
Communications Systems3,425
3,165
10,544
16,403
Total Revenues43,371
35,694
142,678
120,604








Cost of Products Sold:






Battery & Energy Products31,126
24,482
101,039
77,215
Communications Systems2,626
2,530
7,674
11,674
Total Cost of Products Sold33,752
27,012
108,713
88,889








Gross Profit9,619
8,682
33,965
31,715








Operating Expenses:






Research and Development2,855
2,101
7,577
5,854
Selling, General and Administrative7,715
6,070
21,684
17,370
Total Operating Expenses10,570
8,171
29,261
23,224








Operating (Loss) Income(951)
511
4,704
8,491








Other Expense800
158
2,896
685
(Loss) Income Before Income Taxes(1,751)
353
1,808
7,806








Income Tax (Benefit) Provision(504)
74
306
1,630








Net (Loss) Income(1,247)
279
1,502
6,176








Net (Loss) Income Attributable to Non-Controlling Interest(27)
21
(22)
58








Net (Loss) Income Attributable to Ultralife Corporation($1,220)
$258
$1,524
$6,118
















Net (Loss) Income Per Share Attributable to Ultralife Common Shareholders – Basic($.07)
$.02
$.09
$.37








Net (Loss) Income Per Share Attributable to Ultralife Common Shareholders – Diluted($.07)
$.02
$.09
$.37








Weighted Average Shares Outstanding – Basic16,646
16,625
16,638
16,530








Weighted Average Shares Outstanding – Diluted16,646
16,874
16,699
16,742


Non-GAAP Financial Measures

Adjusted EBITDA

In evaluating our business, we consider and use adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance in addition to GAAP financial measures. We define adjusted EBITDA as net income attributable to Ultralife Corporation before net interest expense, provision for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expense/income that we do not consider reflective of our ongoing continuing operations. We reconcile adjusted EBITDA to net income attributable to Ultralife Corporation, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.



ULTRALIFE CORPORATION AND SUBSIDIARIES
CALCULATION OF ADJUSTED EBITDA
(Dollars in Thousands)
(Unaudited)





Three-Month Period Ended
Nine-Month Period Ended

September 30,
2025

September 30,
2024

September 30,
2025

September 30,
2024








Net (Loss) Income Attributable to Ultralife Corporation($1,220)
$258
$1,524
$6,118
Adjustments:






Interest Expense, Net992
173
3,016
1,111
Income Tax (Benefit) Provision(504)
74
306
1,630
Depreciation Expense1,008
765
2,966
2,294
Amortization Expense411
229
1,226
684
Stock-Based Compensation Expense236
170
698
490
Severance and Other Costs for Plant Closure491
-
641
-
Acquisition and Other Non-Recurring Costs594
250
1,112
-
Non-Cash Purchase Accounting Adjustment40
-
120
250
Adjusted EBITDA$2,048
$1,919
$11,609
$12,577


Company Contact:
Ultralife Corporation
Philip A. Fain
(315) 210-6110
pfain@ulbi.com

Investor Relations Contact:
Alliance Advisors IR
Jody Burfening/Alex Villalta
(212) 838-3777
avillalta@allianceadvisors.com


Recommended Reading